Neoadjuvant therapy for gastric cancer: current evidence and future directions.
暂无分享,去创建一个
[1] D. Fraker,et al. Omission of adjuvant therapy after gastric cancer resection: development of a validated risk model. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[3] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[4] D. Fraker,et al. Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the National Cancer Data Base , 2014, Cancer.
[5] D. Richel,et al. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] D. Fraker,et al. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. , 2014, Surgery.
[7] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[8] Long Bai,et al. HER2‐positive patients receiving trastuzumab treatment have a comparable prognosis with HER2‐negative advanced gastric cancer patients: A prospective cohort observation , 2014, International journal of cancer.
[9] M. Gonen,et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[11] D. Smith,et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Ajani,et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] E W Steyerberg,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.
[14] M. Shah,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] W. Hohenberger,et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Yachida,et al. Pilot Feasibility Study of Neoadjuvant Chemoradiotherapy with S-1 in Patients with Locally Advanced Gastric Cancer Featuring Adjacent Tissue Invasion or JGCA Bulky N2 Lymph Node Metastases , 2012, Annals of Surgical Oncology.
[17] C. Montagut,et al. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Joon-Oh Park,et al. Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer , 2012, Cancer Chemotherapy and Pharmacology.
[19] Y. Bang,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.
[20] Joon-Oh Park,et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Sutradhar,et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer , 2012, Gastric Cancer.
[22] Y. Ohashi,et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Shah,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] H. Putter,et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) , 2011, BMC Cancer.
[25] J. Pignon,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Schlag,et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[28] Yasuo Ohashi,et al. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer , 2009 .
[29] M. Stuschke,et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Heslin,et al. Prognostic factors and preoperative radiation therapy associated with sphincter preservation in patients with resectable rectal cancer. , 2008, American journal of surgery.
[31] Y. Ohashi,et al. Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa‐negative, locally advanced gastric cancer , 2007, The British journal of surgery.
[32] Yasuo Ohashi,et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.
[33] C. Fuchs,et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Goldhirsch,et al. Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. , 2007, Journal of the National Cancer Institute.
[35] F. Ciardiello,et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Laura H. Tang,et al. Clinical Correlation of Endoscopic Ultrasonography with Pathologic Stage and Outcome in Patients Undergoing Curative Resection for Gastric Cancer , 2007, Annals of Surgical Oncology.
[37] J. Wydmański,et al. The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[38] P. Catalano,et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] J. Ajani,et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[41] A. Tres,et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] M. Ychou,et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] J. Ajani,et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Zembala,et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer , 2004, Gastric Cancer.
[45] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[46] H. Putter,et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[47] J. Ajani,et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] J. Fleshman,et al. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. , 2003, International journal of radiation oncology, biology, physics.
[49] Aller,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.
[50] L. Mariani,et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] D. Parkin,et al. Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.
[52] J. Ajani,et al. A Pilot Study of Preoperative Chemoradiotherapy for Resectable Gastric Cancer , 2001, Annals of Surgical Oncology.
[53] V. Schumpelick,et al. Endoscopic ultrasonography in the preoperative staging of gastric cancer , 2000, Surgical Endoscopy.
[54] S. Hundahl,et al. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy , 2000, Cancer.
[55] S. Curley,et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] D. Gouma,et al. Extended lymph-node dissection for gastric cancer. , 1999, The New England journal of medicine.
[57] A. Soumilas,et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. , 1996, Chemotherapy.
[58] T. Fleming,et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A southwest oncology group study , 1995, Annals of Surgical Oncology.
[59] R. Labianca,et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] H. Wieand,et al. A prospective, randomized evaluation of intensive‐course 5‐fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer , 1991, Cancer.
[61] D. Amadori,et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] P. Lavin,et al. Postoperative adjuvant 5‐fluorouracil plus methyl‐CCNU therapy for gastric cancer patients. Eastern cooperative oncology group study (EST 3275) , 1985, Cancer.
[63] A. Ejaz,et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. , 2015, Journal of the American College of Surgeons.
[64] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[65] J. Ajani,et al. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[66] S. Barni,et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. , 2007, Journal of the National Cancer Institute.
[67] P. Morel,et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] M. Huguier,et al. [Extended lymph-node dissection for gastric cancer]. , 1999, Chirurgie; memoires de l'Academie de chirurgie.
[69] C. Pera,et al. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. , 1993, European journal of cancer.
[70] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.